TABLE 2.

Predicted MHC class I and II epitopes of the designed virus-like particle (VLP)-based vaccine.

HLA sets in HBV	MHC	Allele	Position	Sequence	Percentile rank*
Common	MHC I	HLA-A*02:01	18–27, 253–262	FLPSDFFPSV	0.11
	MHC II	HLA-DRB1*01:01	163–177, 382–396	ETVLEYLVSFGVWIR	4.4
Non-responder	MHC I	HLA-B*08:01	214–222, 222–230, 431–444, 441–449	SPRRRRSQS	0.3
			207–215, 426–434	SPRRRTPSP	0.2
			150–158, 369–377	LLWFHISCL	0.5
			142–150, 361–369	NMGLKIRQL	1
	MHC II	HLA-DRB1*03:01	20–34, 255–269	PSDFFPSVRDLLDTA	7.1
		HLA-DRB1*07:01	162–176, 381–395	RETVLEYLVSFGVWI	2.8
			144–158, 363–377	GLKIRQLLWFHISCL	7
		HLA-DQB1*02:01	11–25, 246–260	ATVELLSFLPSDFFP	0.77
			5–19, 240–254	PYKEFGATVELLSFL	0.92
			13–27, 248–262	VELLSFLPSDFFPSV	0.94
			10–24, 245–259	GATVELLSFLPSDFF	0.97
Positive responsive	MHC II	HLA-DRB1*13:01	163–177, 382–396	ETVLEYLVSFGVWIR	0.53
			169–183, 388–402	LVSFGVWIRTPPAYR	0.53
		HLA-DRB1*15:01	163–177, 382–396	ETVLEYLVSFGVWIR	0.84
		HLA-DRB1*04:01	132–146, 351–365	RDLVVNYVNTNMGLK	2.5

*Percentile rank ≤1: high-affinity peptide sequences with the antigenic property; percentile rank ≤10: intermediate-affinity peptide sequences with the antigenic property.